Infectious Diseases | Mount Sinai Today

I Recovered From COVID-19. How Do I Get Back In Shape?

May 17, 2021 | COVID-19, Rehab Medicine, Your Health

If you are one of the millions who contracted COVID-19 in the past year, you may still be in the process of regaining the physical fitness lost from when the virus forced you to slow down and heal.

Joseph Herrera, DO, Chair of Rehabilitation and Human Performance for the Mount Sinai Health System, and cardiology fellow Saman Setareh-Shenas, MD, explain how those who have recovered from COVID-19 can get back into their pre-illness shape and how the Mount Sinai Post-COVID Care Center can assist them on their road to recovery. Two key takeaways: Take it slow and consider seeing a specialist if you encounter any hurdles along the way.

How does the effect of COVID-19 on the body influence my recovery?

Joseph Herrera, DO: We are seeing a range of symptoms, from mild to severe, in patients after being infected with COVID-19. The virus affects them both physically and cognitively, everything from increased fatigue, shortness of breath, and tachycardia, a medical term of a rapid heartbeat, and difficulty concentrating, also known as brain fog. Because of this, some patients find it difficult to get back to their pre-COVID level of physical activity.

What about athletes? Does COVID-19 affect them differently?

Dr. Herrera: We’ve seen a range of people who have been impacted by COVID-19, from recreational athletes to marathon runners and professional athletes. I would say that they, similar to the general population, have a range of symptoms, some very mild all the way to severe. Overall, I don’t think your pre-infection conditioning really prevents anything.

Saman Setareh-Shenas, MD: COVID-19 doesn’t discriminate between athletes and non-athletes. We have seen major effects from the virus as well as post-COVID syndrome in very healthy athletes.

When is it safe to resume physical activity after recovering from COVID-19?

Dr. Herrera: We’ve been advising symptom-free patients to resume activity as tolerated. If they’ve been hospitalized due to COVID-19 or have spent a prolonged time in bed while recovering, whether in an intensive care unit bed or in their home, we want to make sure that they can return to normal activity before progressing to exercise.

Dr. Setareh-Shenas: Early on in the pandemic as the initial wave of patients were recovering, we started noticing a lot of our patients were not immediately able to go back to their baseline exercise level.

At the Mount Sinai Post-COVID Care Center, we help patients regain their pre-COVID strength and conditioning by using recommendations based on guidelines by the Leadership Council of the Sports and Exercise Cardiology Section of the American College of Cardiology and findings by British researchers. These guidelines advise those in recovery to return to exercise very gradually. Don’t go back to where your baseline was. Wait at least seven to 10 days, and then take it slowly from there.

Dr. Herrera: We guide patients using the ‘rule of tens.’ For example, if a patient were lifting a hundred pounds prior to getting infected with COVID-19, we have them cut everything in half—or even a quarter—of the weight they previously lifted. Then we apply the ‘rule of tens,’ by increasing either the intensity or the duration of exercise by 10 percent every 10 days. This way, they have a gradual increase in activity.

What precautions should post-COVID patients take when getting back to physical activity?

Dr. Setareh-Shenas: In the past year, we have seen a number of patients in our post-COVID population who are experiencing heart racing, palpitations, or a new arrhythmia. So, as a precaution, I would say that patients recovering from COVID-19 who have chest pains or shortness of breath, should be evaluated by their physician or by an expert cardiologist at a Post-COVID Center.

For example, in our Cardiology Clinic within the Post-COVID Care Center at Mount Sinai, we evaluate patients who have complaints of chest pain or shortness of breath and conduct exercise testing to see their maximal exercise capacity and evaluate for any arrythmia during exercise. We want to know: Do they have any symptoms when exercising on the treadmill? Does their heart go under strain that’s not equivalent for their age group and their risk factors? So, patients should be mindful of this, especially if they have a history of cardiac issues.

Dr. Herrera: Most importantly, don’t push yourself too hard but do see a specialist. Get evaluated to see if you qualify for any of the programs that we offer at Mount Sinai.

Get more COVID-19 information from Mount Sinai

What You Need to Know About COVID-19 Vaccination in 12- to 15-Year-Olds

May 13, 2021 | Children's Health, COVID-19, Featured, Vaccines, Your Health

Schools, playgrounds, and, most of all, our children will soon be better protected against COVID-19, thanks to the latest news from the U.S. Food and Drug Administration (FDA). The agency has announced that the Pfizer-BioNTech COVID-19 vaccine is safe and effective for children between the ages of 12 to 15 and authorized emergency use of the vaccine; the CDC also recommends the vaccine in this age group. You may have questions about this new development. Kristin Oliver, MD, MHS, Assistant Professor of Pediatrics, and Environmental Medicine and Public Health, at the Icahn School of Medicine at Mount Sinai, has answers.

How effective is the Pfizer-BioNTech COVID-19 vaccine in children aged 12 to 15?

All indications are that COVID-19 vaccination is highly effective in children ages 12 to 15. In the trial, the vaccine prevented 100 percent of COVID-19 cases among participants who got the vaccine. It’s important to remember that the results we see in clinical trials—called efficacy—may be slightly better than what we see when the vaccine is out in the world—effectiveness. People in the clinical trials always get the vaccine exactly as indicated, but this isn’t always the case in the real world. Once we start immunizing more and more people over time, we’ll have a better sense of the vaccine’s effectiveness for ages 12 to 15, but I expect this will also be really high.

Is it safe?

The COVID-19 vaccine is safe for children ages 12 to 15, just as it is for people 16 and older. In addition, the FDA will continue to monitor safety for another two years.

Researchers at the CDC are investigating a link between COVID-19 vaccines from Pfizer-BioNTech and Moderna and heart inflammation in young men and boys. Myocarditis and pericarditis can be serious but, fortunately, these side effects to vaccination are very rare and the cases connected to receiving the COVID-19 vaccine have been mild. So, the benefits of COVID-19 vaccination in this group still outweigh the risks of getting myocarditis from the vaccine.

Will our children experience any side effects from the vaccine?

We can expect children to have side effects similar to what we’ve seen in adults. The most common are pain and swelling at the injection site, tiredness, and headaches. In the study fewer than one in five 12- 15 year olds who get the shot, had a fever. The good news is that these side effects usually only last for a couple of days and can be treated with over-the-counter medication.

Remember: these types of side effects are a sign that the body’s immune system is responding to the vaccine, which is a good thing. We have seen more of these side effects to the COVID-19 vaccination than, say, the tetanus booster or HPV vaccine. For that reason, you might want to have your child take the vaccine on day when you know they can take is easy the next couple days.

Are there some 12- to 15-year-olds who should not take the vaccine?

Anyone who has had an allergic reaction to any component of the vaccine, or who had an allergic reaction to the first dose of the vaccine, shouldn’t take it.

But peanut, egg, and other food allergies are not a contraindication. If your child has any of these allergies, they can take the vaccine. If you have any questions about your child’s allergies and COVID-19 vaccine, check with your pediatrician.

If my child had COVID-19, do they still need to get a vaccine?

The U.S. Centers for Disease Control and Prevention has said that everyone who can get a COVID-19 vaccine should do so, even if they’ve already had COVID-19. In general, we don’t know how long protection against the virus lasts after an infection, or how well previous infection prevents infection with some of the new variants. In our efforts to keep everyone healthy, the recommendation is to get vaccinated.

What are the benefits of vaccinating children ages 12 to 15 against COVID-19?

Vaccines are an important tool in protecting us from developing COVID-19. It is exciting that children ages 12 to 15 can now get vaccinated—and it is important that they do so. While it is true that younger people are less likely than their elders to get seriously ill and die from COVID-19, they are not immune to the virus. Children can, and have, contracted the virus, gotten seriously ill, and even died. So the first benefit of vaccination is to protect them from the virus and its complications. Additionally, we know that children can transmit the virus to others who are more at risk for serious complications. By vaccinating young teens, we can help prevent that transmission as well as protect grandparents, babysitters, and other more vulnerable people who are in their orbit.

Get more COVID-19 vaccine information from Mount Sinai

Scientists Celebrate International Day of Immunology and Their Role in Advancing Breakthroughs for COVID-19

May 6, 2021 | COVID-19, Featured, Research

Renowned immunologist Miriam Merad, MD, PhD, center, and members of Mount Sinai’s Precision Immunology Institute created T-shirts that support COVID-19 vaccinations in honor of International Day of Immunology.

The significant role the human immune system has played in the spread and containment of the SARS-CoV-2 virus, which causes COVID-19, was the subject of an International Day of Immunology summit, held virtually on Thursday, April 29, 2021, and co-organized by pioneering immunologist Miriam Merad, MD, PhD, Director of the Precision Immunology Institute at the Icahn School of Medicine at Mount Sinai. Dr. Merad, who, in 2020, was elected to the National Academy of Sciences, also serves as Director of Mount Sinai’s Human Immune Monitoring Center.

Scores of prominent researchers from throughout the world gathered at the summit to celebrate the international collaboration that took place during the pandemic and the speed at which their work was translated into desperately needed treatments. Their deep understanding of the different ways in which the human immune system reacts to SARS-CoV-2 has helped guide the worldwide medical response.

Anthony S. Fauci, MD, Director of the National Institute of Allergy and Infectious Diseases, gave opening remarks. “As an immunologist, physician, and U.S. government official, who, for decades, has helped lead the public health response to emerging diseases, it has become clear to me the important role that immunology plays in medicine and in infectious diseases,” he told the audience.

“People with healthy, intact immune systems—such as most young people—can control SARS-CoV-2 infection by limiting its effects to the upper airways in mild symptoms,” Dr. Fauci said. “In contrast, older people or individuals whose immunity is compromised by immunosuppressive agents, or an immune-compromising illness such as cancer, are unlikely to produce a robust immune response that can keep SARS-CoV-2 in check. When the history of this COVID-19 pandemic is written, the discipline of immunology will stand out for its important role in explaining the remarkable protean manifestations of SARS-CoV-2 infection and in enabling us to identify and exploit vulnerabilities in the virus to develop safe and effective vaccines to thwart its pandemic spread.”

Florian Krammer, PhD

The summit’s participants also included Özlem Türecki, MD, Co-founder and Chief Medical Officer of BioNTech, the company that partnered with Pfizer to produce the first authorized mRNA vaccine and the first vaccine to fight COVID-19; and Florian Krammer, PhD, Mount Sinai Professor in Vaccinology at the Icahn School of Medicine at Mount Sinai, who created one of the world’s first antibody tests for SARS-CoV-2.

Dr. Türecki described the development of BioNTech’s mRNA vaccine for COVID-19, which the company dubbed “project light speed,” beginning in January 2020 as soon as virus’ genetic sequence became known. She said BioNTech’s early investment in mRNA technology allowed the company to move quickly, particularly when their scientists expected the pandemic to spread “even faster” than it ultimately did.

BioNTech created 20 vaccine candidates at first, and then pared them down to four. By July, the company selected its “pivotal candidate” for phase 3 efficacy testing. In November, the vaccine was found to be 95 percent effective, and in December, the United States began administering the vaccine under the Food and Drug Administration’s Emergency Use Authorization.

According to Dr. Türecki, BioNTech was able to reach the market quickly by perfecting its manufacturing process at the same time it developed the vaccine. The Pfizer-BioNTech vaccine has now been authorized in more than 65 countries and administered to more than 260 million people.

Dr. Krammer said that eventually, scientists will “disentangle” the many questions that still remain about SARS-CoV-2 and the adaptive human immune system. For example, will people have long lasting immunity? He also questioned whether it would be advantageous to receive two different COVID-19 vaccines rather than the same one twice.

“But there’s a more pragmatic question here,” he said. “We are in a situation right now where we don’t have enough vaccines, and the production rate of the vaccines that are currently produced and licensed is not high enough to cover the globe and a lot of countries are struggling to get access to vaccines.” Improving the situation is critical.

Indeed, Ester C. Sabino, PhD, Professor, Institute of Tropical Medicine, at the University of São Paulo, Brazil, said, “If we don’t have access to vaccines, then probably herd immunity will never be reached.”

Panelist Adrian Hill, DPhil, Director of the Jenner Institute at Oxford University in England, and a co-developer of the AstraZeneca vaccine for COVID-19, concurred. “The biggest failing in responding to COVID-19 has not been in vaccine technology—they perform really well. And it hasn’t been in the speed of response—that’s been extraordinary,” he said. “It’s been in the lack of physical locations that manufacture vaccines widely around the world. We need to have facilities that can flip overnight to make outbreak pathogen vaccines.”

Thousands of Mothers Take Part in Mount Sinai Study of COVID-19 and Pregnancy

May 6, 2021 | BFWHRI, COVID-19, Featured, OB/GYN, Pregnancy, Research

Jill Schechter, with baby Jonah, says she was grateful to participate in the study of COVID-19 and pregnancy.

A multidisciplinary team at Mount Sinai is conducting the first large-scale prospective study to examine the impact of COVID-19 infection during pregnancy on maternal and child outcomes. The study is funded by a $1.8 million contract from the Centers for Disease Control and Prevention (CDC) and is expected to be conducted through May 2022. The team calls it “Generation C” because it is studying the maternal experience during the COVID-19 pandemic.

“Early in the pandemic, there were reports that women who tested positive during delivery might have a higher risk of birth complications,” says a co-investigator, Veerle Bergink, MD, PhD, Professor of Psychiatry, and Obstetrics, Gynecology and Reproductive Science, Icahn School of Medicine at Mount Sinai. “We want to know, not only for symptomatic women but also for the asymptomatic women, what exposure to COVID-19 means for your obstetric outcomes and for your baby.”

The research team intends to recruit a cohort of 3,000 pregnant patients at The Mount Sinai Hospital and Mount Sinai West, with more than 2,500 enrolled to date.

One participant in the study is also a co-investigator—Whitney Lieb, MD, MPH, MS, Assistant Professor of Obstetrics, Gynecology and Reproductive Science, Population Health Science and Policy, and Medical Education, Icahn Mount Sinai. “There is limited data about how COVID-19 affects moms and babies, and I think it is important to get as much data as possible,” says Dr. Lieb, who gave birth at Mount Sinai West in July 2020. “That is why I decided to join the study.”

Whitney Lieb, MD, with baby Jacob, is both a participant and a co-investigator in the study. “There is limited data about how COVID-19 affects moms and babies,” says Dr. Lieb, Assistant Professor of Obstetrics, Gynecology and Reproductive Science, Icahn School of Medicine at Mount Sinai.

Jill Schechter, who gave birth on Valentine’s Day at The Mount Sinai Hospital, joined for the same reason. Ms. Schechter was vaccinated for COVID-19 while pregnant and asked her physician if there were any studies she could participate in. “I work in health care, and I am aware of the importance of research,” Ms. Schechter says. “I’m grateful for being able to participate.”

In the study, researchers are examining plasma samples drawn as part of routine care at each trimester of pregnancy in all pregnant women at the two hospitals. Samples are tested for the immunoglobulin M and immunoglobulin G antibodies to SARS-CoV-2, the virus that causes COVID-19, at each trimester of pregnancy and delivery. The team is measuring a panel of inflammatory biomarkers at each trimester of pregnancy and at delivery. The hypothesis is that the level of inflammatory host response to SARS-CoV-2 exposure is related to the impact of the infection on maternal and child outcomes, and that timing is crucial.

The study is examining the subjects’ electronic medical records, obtaining data on obstetric complications, miscarriage, premature rupture of membranes, delivery type, maternal ICU admissions, acute respiratory distress syndrome, sepsis, and maternal death. In addition, the team is extracting data on fetal growth and neonatal outcomes, including birth weight, preterm birth, neonatal morbidities, neonatal intensive care admissions, congenital malformations, and fetal and neonatal death.

“We are looking at the impact and timing of SARS-CoV-2 infection and the development of COVID-19 on these acute and severe complications,” says co-principal investigator Joanne Stone, MD, Director of the Division of Maternal Fetal Medicine, Mount Sinai Health System, and Professor of Obstetrics, Gynecology and Reproductive Science. “The aim is to investigate whether SARS-CoV-2 infection and a strong inflammatory host response are related to preterm delivery and neonatal morbidity.”

Another aim of the study is to examine the extent to which COVID-19 disproportionately impacts pregnant women from underserved communities. This part of the study is taking full advantage of the diversity of Mount Sinai’s patient population. “We have women from the affluent Upper East Side of Manhattan, from the Bronx, from Harlem,” says co-principal investigator Siobhan Dolan, MD, MPH, Vice Chair for Research and Director of Genetics and Genomics, Department of Obstetrics, Gynecology and Reproductive Science, and Co-Director of the Blavatnik Family Women’s Health Research Center. “The ethnic and socioeconomic diversity of our patients means that we do a very good job of reflecting the United States population.”

The World Health Organization classifies pregnant women as at high risk for serious COVID-19-related morbidity and mortality. The Mount Sinai study was proposed in response to a CDC call for research that will bolster the very limited data now available on the effects of SARS-CoV-2. It was designed by Dr. Bergink and Elizabeth Howell, MD, MPP, who is now Chair of Obstetrics and Gynecology at the Perelman School of Medicine at the University of Pennsylvania.

“This virus will be among us for a while,” Dr. Bergink says, “and it is good to have real-life data on the effects of COVID-19, especially in vulnerable groups, like pregnant women and high-risk populations.”

Did You Gain Weight During Quarantine? Here’s How to Lose it.

May 5, 2021 | COVID-19, Diet and Nutrition, Your Health

Have you gained any weight since the stay-at-home orders were issued in March of 2020? If so, you are not alone. The American Psychological Association’s “Stress in America” poll found that 61 percent of its 3,013 adult respondents experienced undesired weight changes during the COVID-19 pandemic, with 42 percent reporting they gained more weight than they intended. The median weight gain was 15 pounds.

Whether it is 15 pounds or the “Quarantine 19,” studies have found that stress, in this case generated by the health crisis, influences changes in eating patterns and increases the desire for foods high in fat and sugar. Excessive weight gain and obesity is a risk factor for developing potentially life-threatening health problems, including COVID-19.

You can begin to make changes in your lifestyle to lose this weight. Mary Graffagnino, Chief Dietitian at Mount Sinai South Nassau, offers these 10 simple steps:

Eat more veggies, fresh fruits, nuts, seeds, and whole grains.
Avoid processed foods, such as baked goods, ready-to-eat meals, and meat products, such as bacon, sausage, and salami.
Avoid sugary snacks and beverages.
Engage in regular physical exercise. Get at least 150 minutes each week.
Eat breakfast every day. Skipping the first meal of the day makes you hungrier for the next one.
Make sure you get enough sleep. Insufficient sleep is linked to a higher risk of obesity.
Do not be a member of the “clean-plate” club. Leave a few bites of food on your plate, especially when eating out.
Eat mindfully and savor your food. Consider putting away your phone at meal time.
Control your portion size. If you crave a chocolate bar, have a smaller size or half a bar. One serving of meat or poultry should fit in the palm of your hand, or no bigger than a deck of cards
Keep a food journal. Jot down all the meals and snacks you have eaten throughout the day.

Get some healthy snack ideas from Mount Sinai

Can COVID-19 Spread Faster in an Air Conditioned House?

May 3, 2021 | COVID-19, Health Hub, Your Health

As the weather begins to turn warmer and people spend more time at home, many will be thinking about cranking up the AC. Some might wonder whether COVID-19 can spread faster in an air conditioned home.

Waleed Javaid, MD, Associate Professor of Medicine (Infectious Diseases) at the Icahn School of Medicine at Mount Sinai in New York City, says it is possible, but not likely.

If someone in the house who is infected with the virus is coughing and sneezing and not being careful, then tiny virus particles in respiratory droplets could be circulated in the air. Anything that moves air currents around the room can spread these droplets, whether it is an air conditioning system, a window-mounted AC unit, a forced heating system, or even a fan, according to Dr. Javaid.

But he notes the added risk is limited and can be overcome with careful observance of the general rules for minimizing the spread of the virus. The most important point is that people with the virus should be very careful about covering their mouth and nose when they cough or sneeze. Anyone who is infected should stay in an out-of-the way part of the residence, away from others, he says. Those in the residence should treat others as if they could be infected with the virus by maintaining a safe distance and frequently washing their hands.

One thing you can do if you are a homeowner and have a forced air heating and cooling system is ensure that the air filter in your unit is replaced according to the filter instructions, he said. Some filters are designed to remove particles such as respiratory droplets.

Also, opening a window can help bring in fresh air from the outside and disperse stale air inside, and that could help reduce the possibility of the spread of the virus particles in the house.

Questions about the possible role of air conditioners in spreading the virus arose after the Centers for Disease Control and Prevention recently posted a paper to be published in the July 2020 issue of an agency publication. In the paper, Chinese researchers traced an outbreak of COVID-19 to the air flow in an air-conditioned restaurant and recommended increasing the distance between tables and improving ventilation.

Currently, one of the best ways to protect against COVID-19 is to get yourself, and all eligible household members, vaccinated. Vaccination has been proven to reduce the risk of contracting COVID-19 as well as transmitting the illness.

If you would like to get a COVID-19 vaccine, contact your state or local health department for scheduling information.

New York State New York City

New Jersey Connecticut

« Older Entries

Next Entries »